Pauline Belujon1, Anthony A Grace2. 1. Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania.. Electronic address: belujon@pitt.edu. 2. Departments of Neuroscience, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: One of the most novel and exciting findings in major depressive disorder research over the last decade is the discovery of the fast-acting and long-lasting antidepressant effects of ketamine. Indeed, the therapeutic effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer to be expressed, with about a third of major depressive disorder patients resistant to treatment. Clinical studies have shown that a low dose of ketamine exhibits fast-acting relatively sustained antidepressant action, even in treatment-resistant patients. However, the mechanisms of ketamine action at a systems level remain unclear. METHODS: Wistar-Kyoto rats were exposed to inescapable, uncontrollable footshocks. To evaluate learned helplessness behavior, we used an active avoidance task in a shuttle box equipped with an electrical grid floor. After helplessness assessment, we performed in vivo electrophysiological recordings first from ventral tegmental area dopaminergic (DA) neurons and second from accumbens neurons responsive to fimbria stimulation. Ketamine was injected and tested on helpless behavior and electrophysiological recordings. RESULTS: We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression. We show that part of the antidepressant effect of ketamine is via the DA system. Indeed, injection of ketamine restores a decreased dopamine neuron population activity, as well as synaptic plasticity (long-term potentiation) in the hippocampus-accumbens pathway, via, in part, activation of D1 receptors. CONCLUSIONS: This work provides a unique systems perspective on the mechanisms of ketamine on a disrupted limbic system.
BACKGROUND: One of the most novel and exciting findings in major depressive disorder research over the last decade is the discovery of the fast-acting and long-lasting antidepressant effects of ketamine. Indeed, the therapeutic effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer to be expressed, with about a third of major depressive disorderpatients resistant to treatment. Clinical studies have shown that a low dose of ketamine exhibits fast-acting relatively sustained antidepressant action, even in treatment-resistant patients. However, the mechanisms of ketamine action at a systems level remain unclear. METHODS: Wistar-Kyoto rats were exposed to inescapable, uncontrollable footshocks. To evaluate learned helplessness behavior, we used an active avoidance task in a shuttle box equipped with an electrical grid floor. After helplessness assessment, we performed in vivo electrophysiological recordings first from ventral tegmental area dopaminergic (DA) neurons and second from accumbens neurons responsive to fimbria stimulation. Ketamine was injected and tested on helpless behavior and electrophysiological recordings. RESULTS: We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression. We show that part of the antidepressant effect of ketamine is via the DA system. Indeed, injection of ketamine restores a decreased dopamine neuron population activity, as well as synaptic plasticity (long-term potentiation) in the hippocampus-accumbens pathway, via, in part, activation of D1 receptors. CONCLUSIONS: This work provides a unique systems perspective on the mechanisms of ketamine on a disrupted limbic system.
Authors: Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace Journal: Neuropsychopharmacology Date: 2011-05-11 Impact factor: 7.853
Authors: Kay M Tye; Julie J Mirzabekov; Melissa R Warden; Emily A Ferenczi; Hsing-Chen Tsai; Joel Finkelstein; Sung-Yon Kim; Avishek Adhikari; Kimberly R Thompson; Aaron S Andalman; Lisa A Gunaydin; Ilana B Witten; Karl Deisseroth Journal: Nature Date: 2012-12-12 Impact factor: 49.962
Authors: Millie Rincón-Cortés; Kimberly G Gagnon; Hannah K Dollish; Anthony A Grace Journal: Neuropsychopharmacology Date: 2018-06-18 Impact factor: 7.853
Authors: Jonathan Fischell; Adam M Van Dyke; Mark D Kvarta; Tara A LeGates; Scott M Thompson Journal: Neuropsychopharmacology Date: 2015-04-22 Impact factor: 7.853
Authors: Henry W Chase; Mareike Clos; Sofia Dibble; Peter Fox; Anthony A Grace; Mary L Phillips; Simon B Eickhoff Journal: Neuroimage Date: 2015-03-14 Impact factor: 6.556
Authors: Katharina Klinger; Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace Journal: Eur Neuropsychopharmacol Date: 2019-07-29 Impact factor: 4.600
Authors: Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould Journal: J Pharmacol Exp Ther Date: 2016-07-28 Impact factor: 4.030